Navigation Links
Bunge Responds to Syngenta Suit
Date:8/23/2011

ST. LOUIS, Aug. 23, 2011 /PRNewswire/ -- Bunge North America, the North American operating arm of Bunge Limited (NYSE: BG), issued the following statement which can be attributed to Soren Schroder, Bunge North America president and CEO.

"Bunge North America is aware from press reports of Syngenta's allegations.  From what we know and from prior conversations with Syngenta, we are surprised and disappointed that Syngenta has taken an action which could put at risk a major export market for U.S. corn producers -- China.

Bunge is a strong proponent of agricultural biotechnology and the benefits it offers to the entire value chain.  We have communicated to Syngenta on several occasions that Bunge looks forward to accepting Agrisure® Viptera™ once approval from China is secured.  We understand that Syngenta expects this will happen in early 2012.

However, until this approval occurs, we must protect the integrity of our export supply chain by not accepting Agrisure Viptera and other varieties that do not have major export market approval.  Our obligation to our farmer customers is to provide access to the global marketplace and the price benefits of that access.  Syngenta's decision to commercialize Agrisure Viptera should not foreclose our ability to sell to a major market – China.

Bunge's decision not to accept Agrisure Viptera is consistent with the North American Export Grain Association's (NAEGA) policy to advocate that technology providers receive all major international approvals for a trait prior to seed sales.  The grain export industry, which includes Bunge, notified Syngenta more than a year ago that China is considered a major export market.

According to the U.S. Department of Agriculture, China is currently the seventh largest destination for U.S. corn with imports expected to grow significantly this year."


'/>"/>
SOURCE Bunge North America
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SG Biofuels and Bunge Form Strategic Alliance to Process Jatropha Seeds Into Sustainable Crude Oil
2. Bunge Limited to Expand Sugar and Bioenergy Business in Brazil
3. Bunge Limited Schedules Third Quarter 2008 Earnings Release and Conference Call
4. HCCS Responds to Recent Tornados, Earthquakes and Flooding With Free Online Training Course for Disaster Preparedness
5. Virtual reality helps researchers track how brain responds to surroundings
6. Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
7. China Biologic Products Responds to Allegations on Financial Websites
8. Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification
9. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
10. Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases
11. Immucor Responds To FDA Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
Breaking Biology Technology:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):